Children with Localized Crohn's Disease Benefit from Early Ileocecal Resection and Perioperative Anti-Tumor Necrosis Factor Therapy

 

 Buy Article Permissions and Reprints

Abstract

Introduction In pediatric Crohn's disease ileocecal resection is performed reluctantly as postoperative recurrence is frequent. Anti-tumor necrosis factor (TNF) therapy reduces postoperative recurrence rates but increases the risk for infections.

Materials and Methods We retrospectively reviewed pediatric Crohn's disease patients who underwent ileocecal resection in our center. We compared disease activity and z-scores for height, weight, and body mass index of patients, who continuously received perioperative anti-TNF therapy (TNF + ), with those who did not (TNF–).

Results Of 29 patients (48% females), 13 and 16 were grouped to TNF+ and TNF–, respectively. Patients' characteristics did not differ between groups, except a longer follow-up time in TNF–. We saw significant postoperative improvement but no normalization in z-scores for weight (1.78 vs. 0.77, p < 0.001), body mass index (1.08 vs. 0.22, p < 0.001), and height (0.88 vs. 0.66, p < 0.001). Disease activity improved significantly more in patients receiving anti-TNF therapy (moderate improvement in 83% vs. 31%, p = 0.02). Endoscopic recurrence was more frequent in patients without anti-TNF therapy (80% vs. 20%; p = 0.023), but endoscopic follow-up was incomplete. There was no increase of infections under perioperative anti-TNF therapy (1 patient each; p = 1.000).

Conclusion In patients with localized Crohn's disease an ileocecal resection leads to short-term postoperative improvement of disease activity, body mass index, weight, and growth. For relevant catch-up growth an earlier intervention is necessary. Continuous perioperative anti-TNF therapy had no increased risk of perioperative infections.

Publication History

Received: 13 November 2022

Accepted: 31 January 2023

Article published online:
16 March 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Wittig R, Albers L, Koletzko S, Saam J, von Kries R. Pediatric chronic inflammatory bowel disease in a German Statutory Health INSURANCE-incidence rates from 2009 to 2012. J Pediatr Gastroenterol Nutr 2019; 68 (02) 244-250
  CrossrefPubMedGoogle Scholar
• 2 Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J Clin Gastroenterol 2012; 46 (07) 581-589
  CrossrefPubMedGoogle Scholar
• 3 Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc 2017; 92 (07) 1088-1103
  CrossrefPubMedGoogle Scholar
• 4 Bemelman WA, Allez M. The surgical intervention: earlier or never?. Best Pract Res Clin Gastroenterol 2014; 28 (03) 497-503
  CrossrefPubMedGoogle Scholar
• 5 Amil-Dias J, Kolacek S, Turner D. et al; IBD Working Group of ESPGHAN (IBD Porto Group). Surgical management of Crohn disease in children: guidelines from the Paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr 2017; 64 (05) 818-835
  CrossrefPubMedGoogle Scholar
• 6 Gionchetti P, Dignass A, Danese S. et al; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: part 2: surgical management and special situations. J Crohn's Colitis 2017; 11 (02) 135-149
  CrossrefPubMedGoogle Scholar
• 7 Turner D, Ricciuto A, Lewis A. et al; International Organization for the Study of IBD. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160 (05) 1570-1583
  CrossrefPubMedGoogle Scholar
• 8 Amaro F, Chiarelli F. Growth and puberty in children with inflammatory bowel diseases. Biomedicines 2020; 8 (11) 458
  CrossrefPubMedGoogle Scholar
• 9 Yerushalmy-Feler A, Assa A. Pharmacological prevention and management of postoperative relapse in pediatric Crohn's disease. Paediatr Drugs 2019; 21 (06) 451-460
  CrossrefPubMedGoogle Scholar
• 10 Diederen K, de Ridder L, van Rheenen P. et al. Complications and disease recurrence after primary ileocecal resection in pediatric Crohn's disease: a multicenter cohort analysis. Inflamm Bowel Dis 2017; 23 (02) 272-282
  CrossrefPubMedGoogle Scholar
• 11 Regueiro M, Feagan BG, Zou B. et al; PREVENT Study Group. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. Gastroenterology 2016; 150 (07) 1568-1578
  CrossrefPubMedGoogle Scholar
• 12 Conrad MA, Kelsen JR. The Treatment of pediatric inflammatory bowel disease with biologic therapies. Curr Gastroenterol Rep 2020; 22 (08) 36
  CrossrefPubMedGoogle Scholar
• 13 Walters TD, Kim MO, Denson LA. et al; PRO-KIIDS Research Group. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology 2014; 146 (02) 383-391
  CrossrefPubMedGoogle Scholar
• 14 van Rheenen PF, Aloi M, Assa A. et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohn's Colitis 2020; 15 (02) 171-194
  CrossrefPubMedGoogle Scholar
• 15 Patel SS, Patel MS, Goldfarb M. et al. Elective versus emergency surgery for ulcerative colitis: a National Surgical Quality Improvement Program analysis. Am J Surg 2013; 205 (03) 333-337 , discussion 337–338
  CrossrefPubMedGoogle Scholar
• 16 Gupta RB, Harpaz N, Itzkowitz S. et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133 (04) 1099-1105 , quiz 1340–1341
  CrossrefPubMedGoogle Scholar
• 17 Turner D, Levine A, Walters TD. et al. Which PCDAI version best reflects intestinal inflammation in pediatric Crohn disease?. J Pediatr Gastroenterol Nutr 2017; 64 (02) 254-260
  CrossrefPubMedGoogle Scholar
• 18 Joosten KF, Hulst JM. Malnutrition in pediatric hospital patients: current issues. Nutrition 2011; 27 (02) 133-137
  CrossrefPubMedGoogle Scholar
• 19 Rosario AS, Kurth BM, Stolzenberg H, Ellert U, Neuhauser H. Body mass index percentiles for children and adolescents in Germany based on a nationally representative sample (KiGGS 2003-2006). Eur J Clin Nutr 2010; 64 (04) 341-349
  CrossrefPubMedGoogle Scholar
• 20 Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99 (04) 956-963
  CrossrefPubMedGoogle Scholar
• 21 Turner D, Griffiths AM, Walters TD. et al. Mathematical weighting of the Pediatric Crohn's Disease Activity Index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2012; 18 (01) 55-62
  CrossrefPubMedGoogle Scholar
• 22 Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus Jr EV. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology 2015; 148 (01) 64-76.e2 , quiz e14
  CrossrefPubMedGoogle Scholar
• 23 Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H. IBD Working Group of the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; 50 (Suppl. 01) S1-S13
  CrossrefPubMedGoogle Scholar
• 24 Boualit M, Salleron J, Turck D. et al; EPIMAD Group. Long-term outcome after first intestinal resection in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis 2013; 19 (01) 7-14
  CrossrefPubMedGoogle Scholar
• 25 Pacilli M, Eaton S, Fell JM, Rawat D, Clarke S, Haddad MJ. Surgery in children with Crohn disease refractory to medical therapy. J Pediatr Gastroenterol Nutr 2011; 52 (03) 286-290
  CrossrefPubMedGoogle Scholar
• 26 Ruemmele FM, Veres G, Kolho KL. et al; European Crohn's and Colitis Organisation, European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohn's Colitis 2014; 8 (10) 1179-1207
  CrossrefPubMedGoogle Scholar
• 27 Hammoudi N, Cazals-Hatem D, Auzolle C. et al; REMIND Study Group Investigators. Association between microscopic lesions at ileal resection margin and recurrence after surgery in patients with Crohn's disease. Clin Gastroenterol Hepatol 2020; 18 (01) 141-149.e2
  CrossrefPubMedGoogle Scholar
• 28 Wasmann KATGM, van Amesfoort J, van Montfoort ML, Koens L, Bemelman WA, Buskens CJ. The predictive value of inflammation at ileocecal resection margins for postoperative Crohn's recurrence: a cohort study. Inflamm Bowel Dis 2020; 26 (11) 1691-1699
  CrossrefPubMedGoogle Scholar
• 29 Lau C, Dubinsky M, Melmed G. et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015; 261 (03) 487-496
  CrossrefPubMedGoogle Scholar
• 30 Schad CA, Haac BE, Cross RK, Syed A, Lonsako S, Bafford AC. Early postoperative anti-TNF therapy does not increase complications following abdominal surgery in Crohn's disease. Dig Dis Sci 2019; 64 (07) 1959-1966
  CrossrefPubMedGoogle Scholar
• 31 Schaufler C, Lerer T, Campbell B. et al. Preoperative immunosuppression is not associated with increased postoperative complications following colectomy in children with colitis. J Pediatr Gastroenterol Nutr 2012; 55 (04) 421-424
  CrossrefPubMedGoogle Scholar

• Supplementary Material